ArticleJournal of hepatocellular carcinoma2026
Early Changes in the Neutrophil-to-Lymphocyte Ratio are Associated with Conversion Outcomes in Advanced Hepatocellular Carcinoma Treated with HAIC-Based Triple Therapy.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Reliable early biomarkers for identifying conversion potential during HAIC-based triple therapy in advanced unresectable hepatocellular carcinoma (uHCC) remain lacking. This study evaluated the predictive value of dynamic systemic inflammatory remodeling during treatment. Methods: In this single-center retrospective cohort study, we included 296 patients with advanced uHCC treated with hepatic artery infusion chemotherapy combined with tyrosine kinase inhibitors and immune checkpoint inhibitors. Patients were stratified according to conversion status. ΔNLR was calculated as the NLR measured after the first treatment cycle minus the baseline NLR. Predictors for conversion were identified using logistic regression and evaluated via receiver operating characteristic analysis. A predictive nomogram was subsequently constructed and validated using calibration and decision curve analyses. Results: Among 296 patients, 125 (42.2%) achieved successful conversion resection. Baseline NLR showed minimal predictive value for conversion (AUC = 0.501), whereas ΔNLR demonstrated significantly improved predictive performance (AUC = 0.819). The optimal cohort-derived cutoff was ΔNLR ≤ 0.20, with a sensitivity of 72.0% and a specificity of 91.8%. Multivariate analysis showed that higher ΔNLR was independently associated with lower odds of successful conversion (OR = 0.415, 95% CI: 0.328-0.524, P < 0.001). Patients in the conversion group achieved significantly improved tumor responses, overall survival, and progression-free survival. The nomogram incorporating ΔNLR demonstrated good calibration and clinical utility. Conclusion: Lower ΔNLR values after one treatment cycle were associated with successful conversion resection during HAIC-based triple therapy for advanced uHCC. ΔNLR may serve as a candidate early marker of conversion potential, pending prospective external validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.